米非司酮治疗子宫肌瘤108例临床观察(1)
 |
| 第1页 |
参见附件。
【摘要】 目的 对比观察不同剂量米非司酮治疗子宫肌瘤的临床疗效和安全性。方法 将108例确诊子宫肌瘤的患者分为3组，A组应用米非司酮10 mg/d，B组应用米非司酮25 mg/d，C组应用米非司酮37.5 mg/d；月经第1天始服用，连服3个月为1个疗程。用药前、用药后B超测量子宫及子宫肌瘤的三维径线；用药前和用药3个月后测定促卵泡激素(FSH)、雌二醇(E2)、孕酮(P)、黄体生成素(LH)，检测肝肾功能、血常规，观察服药的不良反应。结果 3组患者治疗期间均闭经，血红蛋白上升，3组子宫及肌瘤体积均明显减小，A组子宫缩小25.7%(P<0.01)，B组子宫缩小27.9%(P<0.01)，C组子宫缩小29.4%(P<0.01)。A组最大肌瘤体积比用药前缩小28.8%(P<0.05)，B组最大肌瘤体积比用药前缩小29.9% (P<0.01)，C组最大肌瘤体积比用药前缩小32.6%(P<0.01)。各组治疗前后对比均差异有统计学意义(P均<0.01)，FSH、E2、P、LH用药前后对比均下降，均差异有统计学意义(P均<0.01)。结论 米非司酮治疗子宫肌瘤疗效好，10 mg/d组不良反应少于其他2组，治疗子宫肌瘤更加安全、有效。
【关键词】
米非司酮；子宫肌瘤；血红蛋白；肌瘤体积
The clinical observation of mifepristone treatment of 180 paitients with vterine fibroids
WANG Huaru.Peoples Hospital of Hainan Province,Hainan 570102,China
【Abstract】 Objective
To observe the effect and different doses of mifepristone treatment of vterine fibroids.Methods 108 cases diagnosed of uterine flesh tumour patients into three groups, A group of 10 mg/d mifepristone influences the application, application of group B get 25 mg/d, application of group C 37.5 mg/d mifepristone influences.Menstruation day 1 beginning taking, and even served three months for a period of treatment. Before use, after B to exceed the womb and the measurement of uterine flesh tumour 3 d diameter line.Drug use 3 months before and after the determination of folliclestimulating hormone (FSH), estradiol (E2), progesterone (P), corpus luteum erythropoietin (LH), liver and kidney function, routine blood test, observe the medicine adverse reactions. Results Three groups of patients during treatment are amenorrhoea, hemoglobin rise, three groups of uterine fibroid volume were significantly reduce and group A uterus down to 25.7% (P<0.01), group B uterine down to 27.9% (P<0.01), group C uterine down to 29.4% (P<0.01). Group A maximum fibroid volume than before drug down to 28 ......
您现在查看是摘要介绍页，详见PDF附件(2529kb)。